Laura Joszt

Laura is the editorial director of The American Journal of Managed Care^® (AJMC^®) and all its brands, including The American Journal of Accountable Care^®, Evidence-Based Oncology™, and The Center for Biosimilars^®. She has been working on AJMC^® since 2014 and has been with AJMC^®'s parent company, MJH Life Sciences^®, since 2011. She has an MA in business and economic reporting from New York University.

You can reach her at ljoszt@mjhlifesciences.com or you can connect with her on LinkedIn or Twitter.

AJMC: The Top 5 Most Popular Biosimilars Content of 2022

December 27, 2022

Article

The American Journal of Managed Care, a sister site of The Center for Biosimilars, looked back at some of the most popular biosimilars content of 2022 to be published on AJMC.com.

New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says

May 30, 2022

Article

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability, the US market is entering a new phase of biosimilar use.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 03, 2022

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia

April 18, 2022

Article

An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.

Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space

April 01, 2022

Article

During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.

Improved Biosimilar Uptake Saved Health System $26.9M Over 2 Years

March 28, 2022

Article

A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

Hospitals, Physician Offices Significantly Mark Up Prices for 3 Drugs With Biosimilars

February 21, 2022

Article

A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.

Biogen to Sell Its Stake in the Biosimilar Venture Samsung Bioepis

January 28, 2022

Article

In a deal to sell the 50% ownership stake, Biogen would receive up to $2.3 billion.

ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis

July 01, 2020

Article

The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).

Gottlieb Stepping Down as FDA Commissioner

March 06, 2019

Article

FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month.